Compare Eli Lilly And Co (LLY) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Marathon Petroleum Corp — how do they compare? Eli Lilly And Co trades at $1,218.97 (market cap $1.08T), while Marathon Petroleum Corp trades at $342.27 (market cap $94.48B). The key difference: Eli Lilly And Co is far larger — about 11.4× Marathon Petroleum Corp's market cap, and Marathon Petroleum Corp pays the higher dividend (1.19%). Which is the better fit depends on your goals.
| LLY | MPC | |
|---|---|---|
Market Cap | $1.08T | $94.48B |
Sector | Health | Energy |
52-Week High | $1.24K | $336.42 |
52-Week Low | $639.43 | $159.11 |
Enterprise Value | $1.13T | $121.00B |
Dividend Yield | 0.57% | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Marathon Petroleum (MPC) trades at $342.47, up 6.91% with strong technical momentum and bullish analyst sentiment. The stock demonstrates robust fundamentals with Q2 2026 EPS of $17.73 beating estimates by 22.1%, supported by refining margin strength and disciplined operations. Valuation metrics remain attractive with P/E of 11.67 and EV/EBITDA of 6.87, while maintaining strong profitability with 47.9% ROE.
MPC presents a compelling investment case with projected revenue growth to $153.6B in 2026 and net profit margin expansion to 5.56%. Key risks include refining margin volatility and geopolitical impacts on energy markets. With 25 buy ratings and no sell recommendations, Wall Street consensus targets $332.70, though current price exceeds this level by 2.9%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
